Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) currently has a daily average trading volume of 1.68M but it saw 821363 shares traded in last market. With a market cap of 55.91M USD, the company’s current market price of $10.00 came falling about -8.68 while comparing to the previous closing price of $10.95. In past 52 weeks, the stock remained buoying in the range of price level as high as $1248.00 and as low as $10.82.
Taking a look at 20-day trading activity of Tonix Pharmaceuticals Holding Corp (TNXP) gives us an average price of $23.33, while its current price level is -99.20% below from 52-week high level whereas it is -7.62% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $27.71 while that of 200 days or SMA-200 reads an average of $103.56. A closer look into the stock’s movement over the week reveals that its volatility is standing at 9.48% during that period while stretching the period over a month that increases to 23.68%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 34.92 which implies that the stock is in neutral territory.
ROTH Capital upgraded its recommendation for the stock as a “Buy” from “Neutral” on April 18, 2019 while assigning a price target of $4. ROTH Capital issued its recommendations for the stock as it upgraded the price target for the stock is $6.
Over the week, TNXP’s stock price is moving -16.25% down while it is -57.54% when we observe its performance for the past one month. Year-to-date it is -69.68% down and over the past year, the stock is showing a downside performance of -99.19%.
The company is expected to be releasing its next quarterly report in March, for which analysts forecasted an EPS of -768 while estimate for next year EPS is -3552. In next quarter, company is expected to be making quarterly sales of $4.2M as analysts are expecting the sales for current fiscal year at $12.8M and seeing the company making $13.35M in sales next year. Moreover, analysts are in estimates of $3.2M for current-quarter revenue.
Currently, Tonix Pharmaceuticals Holding Corp’s total number of outstanding shares is 155.63M with 0.06% of that held by the insiders while 3.32% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -169.47% and return on equity (ROE) at -138.69%. Stock’s beta reads 2.11. Stock has a price to book (P/B) ratio of 20.97 while price to sale or P/S ratio amounts to 4.95. Its return on asset (ROA) is -115.46% on average.
